Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial
In: International journal of cancerReferences, Jg. 146 (2018-11-20), Heft 1
Online
unknown
Zugriff:
In the neoadjuvant WSG-ADAPT-TN trial, 12-week nab-paclitaxel + carboplatin (nab-pac/carbo) was highly effective and superior to nab-paclitaxel + gemcitabine (nab-pac/gem) in triple-negative breast cancer regarding pathological complete response (pCR). Predictive markers for deescalated taxane/carbo use in TNBC need to be identified. Patients received 4 × nab-pac 125 mg/m2 (plus carbo AUC2 or gem 1,000 mg/m2 d1,8 q21). Expression of 119 genes and PAM50 scores by nCounter were available in 306/336 pretherapeutic samples. Interim survival analysis was planned after 36 months median follow-up. Basal-like (83.3%) compared to other subtypes was positively associated with pCR (38% vs. 20%, p = 0.015), as was lower HER2 score (p < 0.001). Proliferation biomarkers were positively associated with pCR, that is, PAM50 proliferation, ROR scores (all p < 0.004), higher Ki-67 (IHC; p < 0.001). For nab-pac/carbo, expression of immunological (CD8, PD1 and PFDL1) genes and proliferation markers (proliferation and ROR scores, MKI67, CDC20, NUF2, KIF2C, CENPF, EMP3 and TYMS) were positively associated with pCR (p < 0.05 for all). For nab-pac/gem, angiogenesis genes were negatively associated with pCR (ANGPTL4: p = 0.05; FGFR4: p = 0.02; VEGFA: p = 0.03). pCR after 12 weeks was strongly associated with favorable outcome (3y event-free survival: 92% vs. 71%, p < 0.001). In early TNBC, basal-like subtype, higher Ki-67 (IHC) and lower HER2 score were, associated with chemosensitivity. Chemoresistance pathways differed between the two taxane based combinations. Combination of proliferation/immune markers and PAM50 subtype could allow patient selection for further deescalated chemotherapy and/or immune treatment approaches.
Titel: |
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial
|
---|---|
Autor/in / Beteiligte Person: | Uleer, Christoph ; Aktas, Bahriye ; Kuemmel, Sherko ; Kates, Ronald E. ; Gebauer, Daniel ; Paré, Laia ; Kolberg-Liedtke, Cornelia ; Wuerstlein, Rachel ; Braun, Michael ; Grischke, Eva-Maria ; Gluz, Oleg ; Pelz, E ; Hackmann, John ; Harbeck, Nadia ; Forstbauer, Helmut ; Christgen, Matthias ; Nitz, Ulrike ; Prat, Aleix ; Schumacher, Claudia ; Kreipe, Hans ; Warm, Mathias |
Link: | |
Zeitschrift: | International journal of cancerReferences, Jg. 146 (2018-11-20), Heft 1 |
Veröffentlichung: | 2018 |
Medientyp: | unknown |
ISSN: | 1097-0215 (print) |
Schlagwort: |
|
Sonstiges: |
|